|
Mar 16
|
US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
|
|
Mar 14
|
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...
|
|
Mar 14
|
Q4 2024 Akebia Therapeutics Inc Earnings Call
|
|
Mar 13
|
Sector Update: Health Care Stocks Slipping Late Afternoon
|
|
Mar 13
|
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 13
|
Akebia Therapeutics: Q4 Earnings Snapshot
|
|
Mar 13
|
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
|
|
Mar 11
|
Exploring High Growth Tech Stocks In The US Market
|